{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:07:22Z","timestamp":1761239242088,"version":"3.40.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"DOI":"10.7759\/cureus.83367","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T01:36:37Z","timestamp":1746236197000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Nemolizumab in Improving Dialysis-Associated Pruritus Refractory to Difelikefalin: A Case Report"],"prefix":"10.7759","author":[{"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"21","author":"Pisoni RL","year":"2006","unstructured":"Pisoni RL, Wikstr\u00f6m B, Elder SJ, et al.. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006, 21:3495-505. 10.1093\/ndt\/gfl461","journal-title":"Nephrol Dial Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira MP","year":"2018","unstructured":"Pereira MP, Steinke S, Zeidler C, et al.. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018, 32:1059-65. 10.1111\/jdv.14570","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2197209","article-title":"Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis","volume":"16","author":"Rastogi A","year":"2023","unstructured":"Rastogi A, Fishbane S, Lerma E. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. Expert Rev Clin Pharmacol. 2023, 16:387-400. 10.1080\/17512433.2023.2197209","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16360","article-title":"Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus","volume":"34","author":"Wieczorek A","year":"2020","unstructured":"Wieczorek A, Krajewski P, Kozio\u0142-Ga\u0142czy\u0144ska M, Szepietowski JC. Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus. J Eur Acad Dermatol Venereol. 2020, 34:2368-72. 10.1111\/jdv.16360","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02047-2","article-title":"Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study","volume":"25","author":"Kinugasa E","year":"2021","unstructured":"Kinugasa E, Igawa K, Shimada H, et al.. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Clin Exp Nephrol. 2021, 25:875-84. 10.1007\/s10157-021-02047-2","journal-title":"Clin Exp Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023, 389:1579-89. 10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10498.x","article-title":"Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis","volume":"165","author":"Fukushi S","year":"2011","unstructured":"Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011, 165:990-6. 10.1111\/j.1365-2133.2011.10498.x","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18377","article-title":"Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances","volume":"36","author":"St\u00e4nder S","year":"2022","unstructured":"St\u00e4nder S, Yosipovitch G, Lacour JP, et al.. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol. 2022, 36:1820-5. 10.1111\/jdv.18377","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.004","article-title":"Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis","volume":"71","author":"Ko MJ","year":"2014","unstructured":"Ko MJ, Peng YS, Chen HY, et al.. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol. 2014, 71:1151-1159.e1. 10.1016\/j.jaad.2014.08.004","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14030197","article-title":"The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect?","volume":"14","author":"\u015awierczy\u0144ska K","year":"2022","unstructured":"\u015awierczy\u0144ska K, Krajewski PK, Nowicka-Suszko D, Bia\u0142ynicki-Birula R, Krajewska M, Szepietowski JC. The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect?. Toxins (Basel). 2022, 14:197. 10.3390\/toxins14030197","journal-title":"Toxins (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.06.023","article-title":"Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis","volume":"152","author":"Guttman-Yassky E","year":"2023","unstructured":"Guttman-Yassky E, Facheris P, Da Rosa JC, et al.. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. J Allergy Clin Immunol. 2023, 152:916-26. 10.1016\/j.jaci.2023.06.023","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093026","article-title":"Cutaneous adverse events following nemolizumab administration: a review","volume":"14","author":"Mima Y","year":"2025","unstructured":"Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med. 2025, 14:3026. 10.3390\/jcm14093026","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/364706-effectiveness-of-nemolizumab-in-improving-dialysis-associated-pruritus-refractory-to-difelikefalin-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T01:36:38Z","timestamp":1746236198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/364706-effectiveness-of-nemolizumab-in-improving-dialysis-associated-pruritus-refractory-to-difelikefalin-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.83367","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}